Fig. 5

DRα1-mMOG-35-55 treatment of TBI: a DRα1-MOG-35-55 treatment (100 μg in 0.1 ml. s.c. given over 10 days starting immediately after FPI) of C57BL/6 male mice reduced TBI neurodeficits, including the modified Neurological Severity Score (mNSS) to evaluate motor, sensory, and balance functions and the corner turning test. *p < 0.05, **p < 0.01. DRα1-mMOG-35-55 treatment reduced lesion size as evaluated by b H&E images of coronal brain tissue sections c quantified at indicated time points after TBI, and d reduced total cell numbers and e activated CD11b⁺CD45^hi microglia/monocytes in the brain and f their surface expression of CD74. g Conversely, DRα1-mMOG-35-55 treatment reduced numbers of CD45^intCD11b⁺CD86⁺ and increased numbers of CD45^intCD11b⁺CD206⁺ microglia on day 3 after TBI. *p < 0.05, **p < 0.01. Reprinted by permission from RightsLink: Springer, Translational Stroke Research, DRα1-MOG-35-55 treatment reduces lesion volumes and improves neurological deficits after traumatic brain injury, Yang et al., copyright 2017 [61]